MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02714nam a22002417a 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20190307085557.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
180719b xxu||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
MSA |
| 082 ## - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.71 |
| Item number |
A.A.I 2018 |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Aya Ali Mohamed. 150423 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
The investigation of antiviral mechanisms of chitosan nanoparticles encapsulating curcumin against Hepatitis C Virus genotype – 4a on human hepatoma cell lines اآلليات المضادة للفيروسات من جسيمات ال Chitosan النانوية<br/>المغلفة بالكركمين ضد النمط الجيني لفيروس االلتهاب الكبدي سي<br/>- 4 أ في خالياالكبدالبشرية \\GP\\Dr. Hossam Taha. ( SPRING 2018 ) |
| Statement of responsibility, etc. |
Aya Ali Mohamed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Giza: |
| Name of publisher, distributor, etc. |
MSA University, |
| Date of publication, distribution, etc. |
2018. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
130 P. :, |
| Other physical details |
26 CM. |
| 440 ## - SERIES STATEMENT/ADDED ENTRY--TITLE |
|---|
| Title |
BIOTECHNOLOGY DISTINGUISHED PROJECTS 2018 |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
Current double and triple treatments with direct acting antivirals (DAAs) were<br/>recently reported to cause several side effects and thereby effective, less toxic<br/>antiviral agents are still needed. Accordingly, this study aimed at investigating the<br/>role of some natural and synthetic antivirals; curcumin, chitosan nanoparticles<br/>(CSNPs) and chitosan encapsulating curcumin nanocomposite on HCV-G4<br/>replication in Huh7.5 cells. Viral Replication was quantified in HCV/G4 infected<br/>Huh7.5 cells either treated or not with curcumin, chitosan nanoparticles (CSNPs)<br/>and chitosan encapsulating curcumin nanocomposite using quantitative real time<br/>PCR assay. Nanocomposite (chitosan nanoparticles encapsulating curcumin) was<br/>successfully prepared and controlled to the size of 15 nm and charges of 25 mV,<br/>characterized by TEM, XRD, FTIR. Curcumin was encapsulated at concentration of<br/>42mg/gm of chitosan nanoparticles. Chitosan nanoparticles at concentration of<br/>100μg/mL showed almost 100% reduction of viral replication whereas the non-toxic<br/>dose of curcumin (13 μm) showed 50% reduction in the viral initial titer as detected<br/>by real-time PCR assay. Combining both agents in the nanocomposite led to a higher<br/>reduction in viral replication. Nanocomposite showed a significant reduction in viral<br/>replication when compared to curcumin and chitosan alone which suggests the<br/>potential role of nanocomposite as a novel, safe and effective antiviral agent.<br/>Keywords: curcumin, chitosan, nanocomposite, HCV – 4. |
| 630 ## - SUBJECT ADDED ENTRY--UNIFORM TITLE |
|---|
| Form subdivision |
Medical Biotechnology |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
antiviral mechanisms. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hepatitis C. |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Samah Loutfy. |
| Relator term |
External Supervisor |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1ferD8oFQTYASOVFbG2JNrYKbA-XeCj1G/view?usp=sharing">https://drive.google.com/file/d/1ferD8oFQTYASOVFbG2JNrYKbA-XeCj1G/view?usp=sharing</a> |
| Public note |
FULL TEXT PRESS HERE |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Gradution Project |
